Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07335913 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of SBS-147 in Healthy Adults
A Phase 1 study of Pain and Pain, Acute, sponsored by Sparian Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT07335913: Recruiting Phase 1 study of Pain and Pain, Acute, sponsored by Sparian Biosciences.
NCT07335913 is a Phase 1 study of Pain and Pain, Acute that is actively recruiting participants, run by Sparian Biosciences. The registered enrollment target is 80 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07335913, a Phase 1 study of Pain and Pain, Acute, is actively recruiting participants, sponsored by Sparian Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is part of the HEAL Initiative supported by the NIH. The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147. Some participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results. The study includes two parts: Single-Dose Group, where Participants receive SBS-147 or placebo one time. Multiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.
Primary Outcome
To assess the number of treatment emergent adverse events experienced in participants after a single dose of SBS-147
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SBS-147
Study Locations (1)
California
- AltaSciences, Inc - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-01-08 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 1 |
What NCT07335913 shows while recruiting
NCT07335913 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07335913 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07335913 about?
NCT07335913 is a clinical study titled "Phase 1 Study of SBS-147 in Healthy Adults". This study is part of the HEAL Initiative supported by the NIH. The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147. Some participants will r...
What is the current status of trial NCT07335913?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2026-01-08. Estimated completion is 2027-02-28.
What conditions does trial NCT07335913 study?
This clinical trial studies the following conditions: Pain, Pain, Acute.
What interventions are being tested in trial NCT07335913?
The interventions under investigation include: Placebo (DRUG), SBS-147 (DRUG).
Who is sponsoring clinical trial NCT07335913?
This trial is sponsored by Sparian Biosciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07335913 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07335913's enrollment target sits among peer trials
80 193rd of 374 higher than 171 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy
RECRUITING · Phase 1
-
Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
RECRUITING · Phase 1
-
Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Patient Controlled Administration of Liquid Acetaminophen
RECRUITING · Phase 1
-
Age-dependent Effects of Smoked and Oral Delta-9-THC
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI